Autologous transplantation of CD133+ BM-derived stem cells as a therapeutic option for dilatative cardiomyopathy

Ghodsizad, Ali; Ruhparwar, Arjang; Marktanner, Ralph; Borowski, A.; Hasani, Motahareh; Poll, L. W.; Vshivkov, I; Stoldt, Volker R.; Voelkel, Tobias; Piechaczek, Christoph; Burchardt, Elmar R.; Stockschlaeder, Marcus; Sucker, Christoph; Gams, E.; Klein, Hans-Martin

doi:10.1080/14653240600735909

Cited by 17 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[14][15][16][17] These nanoparticles present a small crystal size (7-10 nm), high magnetic moment (∼100 meu (g-Fe) -1 ) that align in an applied magnetic field, produce microscopic field gradients that diphase the neighboring proton magnetic moments, and reduce T2 * relaxation time with submillimetric resolution, 10,18 which are advantageous for in vitro and in vivo labeling of CD133 + cells.…”

Section: Introductionmentioning

confidence: 99%

In vitro study of CD133 human stem cells labeled with superparamagnetic iron oxide nanoparticles

Gamarra

Pavon

Marti

et al. 2008

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

In vitro study of CD133 human stem cells labeled with superparamagnetic iron oxide nanoparticles

Gamarra

Pavon

Marti

et al. 2008

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

“…On the basis of these experimental results, clinical trials have been initiated in idiopathic dilated cardiomyopathy. The grafted cells appear to survive better in the host myocardium because myocardial irrigation in this pathology is not significantly impaired [26,27].…”

Section: Nonischemic Cardiomyopathiesmentioning

confidence: 95%

Cellular cardiac regenerative therapy in which patients?

Chachques¹

2009

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Cell-based myocardial regenerative therapy is undergoing experimental and clinical trials in order to limit the consequences of decreased contractile function and compliance of damaged ventricles owing to ischemic and nonischemic myocardial diseases. A variety of myogenic and angiogenic cell types have been proposed, such as skeletal myoblasts, mononuclear and mesenchymal bone marrow cells, circulating blood-derived progenitors, adipose-derived stromal cells, induced pluripotent stem cells, umbilical cord cells, endometrial mesenchymal stem cells, adult testis pluripotent stem cells and embryonic cells. Current indications for stem cell therapy concern patients who have had a left- or right-ventricular infarction or idiopathic dilated cardiomyopathies. Other indications and potential applications include patients with diabetic cardiomyopathy, Chagas heart disease (American trypanosomiasis), ischemic mitral regurgitation, left ventricular noncompacted myocardium and pediatric cardiomyopathy. Suitable sources of cells for cardiac implant will depend on the types of diseases to be treated. For acute myocardial infarction, a cell that reduces myocardial necrosis and augments vascular blood flow will be desirable. For heart failure, cells that replace or promote myogenesis, reverse apoptopic mechanisms and reactivate dormant cell processes will be useful. It is important to note that stem cells are not an alternative to heart transplantation; selected patients should be in an early stage of heart failure as the goal of this regenerative approach is to avoid or delay organ transplantation. Since the cell niche provides crucial support needed for stem cell maintenance, the most interesting and realistic perspectives include the association of intramyocardial cell transplantation with tissue-engineered scaffolds and multisite cardiac pacing in order to transform a passive regenerative approach into a 'dynamic cellular support', a promising method for the creation of 'bioartificial myocardium'.

show abstract

“…Nach durchschnittlich 160 min waren die mononukleären Zellen bereit zur portalvenösen Applikation. Wie auch in früheren Studien beschrieben, wurden Aliquots vom Aspirat und von der injizierten Suspension im Durchflusszytometer untersucht [17,20,24]. Die Zahl der mononukleären Zellen wurde mittels "cell counter" bestimmt (Sysmex, Düsseldorf, Deutschland).…”

Section: Gruppe Mit Pve Und Applikation Von Cd133+-zellenunclassified